2025
Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom.
Im G, Asgharpour A, Aby E, Stine J, Mellinger J, Luther J, Izzy M, Haque L, Lee B, Cotter T, Sherman C, Jophlin L, Goel A, Rice J, Chandna S, Lizaola-Mayo B, Chen P, Singal A, Bansal M. Medications for Weight Loss and MASLD: A National Survey of Hepatology and Gastroenterology Provider Practices, Attitudes, and Knowledge Before Resmetirom. Journal Of Clinical Gastroenterology 2025 PMID: 40549581, DOI: 10.1097/mcg.0000000000002147.Peer-Reviewed Original ResearchWeight loss medicationsGlucagon-like peptide-1Weight lossGastroenterology providersGlucagon-like peptide-1 receptor agonistsPrescribed off-label medicationsPrescribing weight loss medicationsOff-label medicationsFDA-approved medicationsLiver transplant centersOff-label prescribingMedication prescription ratesReceptor agonistsCost/insurance coveragePrescription ratesLiver diseaseSide effectsTransplant centersPeptide-1Steatotic liver diseaseObesity educationBenefit patientsPatientsResmetiromMedicationLow-Dose Oral Minoxidil Initiation for Patients With Hair Loss
Akiska Y, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender V, Castelo-Soccio L, Cotsarelis G, Craiglow B, Desai N, Doche I, Duque-Estrada B, Elston D, Goh C, Goldberg L, Grimalt R, Jabbari A, Jolliffe V, King B, LaSenna C, Lenzy Y, Lester J, Lortkipanidze N, Sicco K, McMichael A, Meah N, Mesinkovska N, Miteva M, Mostaghimi A, Ovcharenko Y, Piliang M, Piraccini B, Rakowska A, Salkey K, Schmidt A, Shapiro J, Sibbald C, Sinclair R, Suchonwanit P, Taylor S, Tosti A, Vañó-Galván S, Wall D, Fu J. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss. JAMA Dermatology 2025, 161: 87-95. PMID: 39565602, DOI: 10.1001/jamadermatol.2024.4593.Peer-Reviewed Original ResearchLow-dose oral minoxidilOral minoxidilExpert consensus statementTopical minoxidilHair lossPediatric patientsConsensus statementModified Delphi processDelphi consensus processEfficacy of topical minoxidilResults of small studiesInternational expert consensus statementsTreating pediatric patientsAdverse effect profileLong-term safetyOff-label useSpecialty consultationOff-label prescribingDelphi processSurvey roundsEvidence-based dataConsensus processExpert panelSublingual minoxidilThird round
2024
Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era
Weleff J, Christian N, Wang J, Singh M, De Aquino J, Saxon A, Vassallo G. Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era. American Journal On Addictions 2024, 34: 85-92. PMID: 39364597, PMCID: PMC11673400, DOI: 10.1111/ajad.13653.Peer-Reviewed Original ResearchSlow-release oral morphineOpioid use disorderBarriers to OUD treatmentAddiction specialistsOpioid use disorder managementUse disorderOUD treatmentThird-line monotherapyFisher's exact testOpioid use disorder treatmentOff-label prescribingOral morphineAgonist opioidsOpioid agonistsOpioid-related overdoseTherapeutic optionsWithdrawal symptomsNovel therapiesExact testOpioidMOUD prescribingSynthetic opioidsClinical practiceClinical approachCompare respondent characteristics
2023
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).
Ganta T, Anker J, Miller E, Tsao K, Oh W. Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2023, 41: e17038-e17038. DOI: 10.1200/jco.2023.41.16_suppl.e17038.Peer-Reviewed Original ResearchMetastatic castration resistant prostate cancerImmune checkpoint inhibitorsOverall survivalResponse rateCastration resistant prostate cancerSingle-center retrospective studyPSA response rateMedian overall survivalResistant prostate cancerOvercome treatment resistanceNon-metastatic diseaseKaplan-Meier curvesOff-label prescribingCheckpoint inhibitorsCancer regimensImmunotherapy regimensMedian durationProstate cancerCombinatorial regimensTreatment resistanceRetrospective studyTreatment paradigmChart reviewHistorical cohortTreatment options
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply